PRWeb The Leader Press Release Distribution
See How PRWeb Works

We're here to help 1-866-640-6397

Login Create Free Account


All Press Releases for November 27, 2007 Subscribe to this News Feed    
 

Sinus MRSA: What to do when Methicillin Resistant Staph Aureus Infects Your Patient

MRSA the "Superbug" is in the news and is more prevalent than ever before. MRSA can also invade the sinuses and cause tough sinus infections, which are difficult to treat. This article discuses treatment options for patients with serious MRSA staph infections in the sinuses and offers solutions to physicians for erradicating these organisms.

Camarillo, CA (PRWEB) November 27, 2007 --- MRSA is in the news now more than ever. The media coined term "Super-bug" may over sensationalize this organism. Nevertheless, resistant Staph infections are serious, and if left untreated, may lead to serious medical complications.

ASL LOGO
ASL LOGO

ASL Pharmacy's Sinus Science™ program has two aerosolized medication formulas effective against MRSA sinus infections: Vancomycin and Mupirocin.

Vancomycin: is a bactericidal antibiotic, which acts by hindering cell wall synthesis and by blocking glycopeptide polymerization. Its spectrum of activity includes many Gram + organisms, including those resistant to other antibiotics. Vancomycin is active against MRSA, Staphylococcus Epidermis and Penicillin Resistant Streptococcal Pneumonia. Tinnitus is not commonly associated with ASL's aerosolized topical application.

Vancomycin Dose: 160mg/3ml Tx time: 5-6 min. approx.

Mupirocin: is a novel antibiotic, which is completely unrelated in chemical structure and mode of action to any other clinically useful class of antibiotics. Mupirocin has the greatest antibacterial activity against aerobic Gram + cocci, such as S. aureus, S. epidermidis, Streptococcus pyogenes and other beta-hemolytic streptococci. Mupirocin is active against most MRSA infections; however, resistance has developed in some areas.

Mupirocin Dose: 3.3mg/2ml Tx time: 4-5 min. approx.

Patient Acceptance: ASL's aerosolized Mupirocin formula is well tolerated by patients as the medication is prepared using a mixture of sterile water and sterile 0.9% NaCl. The ASL preparation does not contain polyethylene glycol (PEG) an ingredient in the topical ointment. (Bactroban®)

The MRSA sinus patient with family members should take extra precaution to wash their hands regularly and cover their mouth and nose when coughing or sneezing to reduce the possibility of infecting others nearby. Family members, likewise, should implement these preventative measures.

Physicians: please call our Sinus Science™ program for further information on how these two important medication therapies treat MRSA inside the sinuses: 866-552-7579. You may fax prescriptions directly to: 866-442-7579.

Aerosol Science Laboratories Inc. is a privately held firm, which specializes in the treatment of Chronic Sinusitis, Perennial Allergic Rhinitis, Allergic Fungal Sinusitis and Sinus Polyps. What makes ASL unique is that they dispense medications that are aerosolized and inhaled through the nasal passages for better medication deposition into the sinuses. For more information contact Cal Tarrant at ASL Pharmacy: 866-552-7579 x223.

###

Post Comment:
Trackback URL: http://www.prweb.com/pingpr.php/SG9yci1FbXB0LUhvcnItSG9yci1UaGlyLVplcm8=

Technorati Tags

Bookmark -  Del.icio.us | Furl It | Technorati | Ask | MyWeb | Propeller | Live Bookmarks | Newsvine | TailRank | Reddit | Slashdot | Digg | Stumbleupon | Google Bookmarks | Sphere | Blink It | Spurl


Other Releases by this Member
OPTIONS
Printer Friendly Version
Download PDF Version
Download Reader Version
BlogThis
ShareThis
CONTACT INFORMATION
CAL TARRANT
ASL Pharmacy
805-236-1679
Email us Here
ATTACHED FILES

Press Release Attachment

Press Release Attachment

ASL LOGO

ASL LOGO

Press Release Attachment

Press Release Attachment

ABOUT PRESS RELEASES
If you have any questions regarding information in these press releases please contact the company listed in the press release. Please do not contact PRWeb. We will be unable to assist you with your inquiry. PRWeb disclaims any content contained in these release. Our complete disclaimer appears here.
 
Close Move